Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy

Concurrent chemoradiotherapy with high-dose cisplatin (100 mg/m2 every 3 weeks) is the preferred regimen with curative intent for patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). This treatment is associated with acute and late toxicities, including...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in Oncology
Main Authors: Sandro V. Porceddu, Florian Scotté, Matti Aapro, Satu Salmio, Ana Castro, Vincent Launay-Vacher, Lisa Licitra
Format: Article
Published: Frontiers Media S.A. 2020-01-01
Subjects:
Cisplatin
Locally advanced squamous cell carcinoma of the head and neck
Toxicity
Cetuximab
Radiotherapy
Chemotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01522/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01522/full

Similar Items